Study to Evaluate the Effect of Micardis® / MicardisPlus® on Metabolic Parameters in Patients With Essential Hypertension and Diabetes Mellitus
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2014-09-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 8148
- Registration Number
- NCT02242825
A Study of a Hypertensive Population Under Treatment With Micardis® and Micardis Plus® to Control the Early Morning BP Rise (SURGE II)
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2014-09-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 5248
- Registration Number
- NCT02242396
Post-Marketing Surveillance of Micardis® (Telmisartan) in Patients With Hypertension
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2014-09-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 6336
- Registration Number
- NCT02242838
Study to Evaluate Efficacy and Safety of Inhaled BEA 2180 BR in COPD Patients
Phase 2
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2014-09-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 37
- Registration Number
- NCT02242279
Study Describing the Hypertensive Population Treated With Telmisartan and Conditions of Use by Medical Practitioners and Patients
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2014-09-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 5018
- Registration Number
- NCT02242851
Study to Evaluate Efficacy and Tolerability of Micardis®/Micardis® Plus in Patients With Hypertension
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2014-09-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 14553
- Registration Number
- NCT02242357
Study to Evaluate the Effect of the Treatment With Micardis® or MicardisPlus® on Blood Pressure
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2014-09-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1527
- Registration Number
- NCT02242864
Evaluation of Efficacy and Tolerability of Micardis® / MicardisPlus® Under Usual Daily-practice Prescribing in Patients With Hypertension
Completed
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2014-09-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 13248
- Registration Number
- NCT02242383
Drug Persistence/Adherence in Patients Treated With Dabigatran or VKA for Stroke Prevention in Non Valvular Atrial Fibrillation (SPAF)
Completed
- Conditions
- Atrial Fibrillation
- Interventions
- First Posted Date
- 2014-09-16
- Last Posted Date
- 2019-04-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1506
- Registration Number
- NCT02240667
Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes
Phase 2
Terminated
- Conditions
- Myelodysplastic Syndromes
- Interventions
- Procedure: Best Supportive Care
- First Posted Date
- 2014-09-16
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 27
- Registration Number
- NCT02240706
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇩🇪Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Germany
🇺🇸Mayo Clinic Cancer Center, Jacksonville, Florida, United States